Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

[1]  Sidney Goldstein,et al.  Effects of Long-Term Monotherapy With Eplerenone, a Novel Aldosterone Blocker, on Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure , 2002, Circulation.

[2]  J. Delyani,et al.  Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. , 2002, Endocrinology.

[3]  K. Weber,et al.  Aldosterone-induced inflammation in the rat heart : role of oxidative stress. , 2002, The American journal of pathology.

[4]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.

[5]  A. Khand,et al.  Prevalence and Incidence of Arrhythmias and Sudden Death in Heart Failure , 2002, Heart Failure Reviews.

[6]  R. Weiss,et al.  The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. , 2002, American journal of physiology. Heart and circulatory physiology.

[7]  S. Rajagopalan,et al.  Mineralocorticoid Receptor Antagonism in Experimental Atherosclerosis , 2002, Circulation.

[8]  N. Reichek,et al.  OR-53: Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy , 2002 .

[9]  Ricardo Rocha,et al.  Aldosterone induces a vascular inflammatory phenotype in the rat heart. , 2002, American journal of physiology. Heart and circulatory physiology.

[10]  G. Ertl,et al.  Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. , 2002, Journal of the American College of Cardiology.

[11]  J. Delyani,et al.  Effect of a selective aldosterone receptor antagonist in myocardial infarction. , 2001, American journal of physiology. Heart and circulatory physiology.

[12]  K. Yee,et al.  Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. , 2001, Journal of the American College of Cardiology.

[13]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[14]  H. Müderrisoğlu,et al.  Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. , 2000, The American journal of cardiology.

[15]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[16]  A. Struthers,et al.  Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. , 2000, Circulation.

[17]  D G Altman,et al.  Calculating the number needed to treat for trials where the outcome is time to an event , 1999, BMJ.

[18]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[19]  A. Struthers,et al.  Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. , 1997, Cardiovascular research.

[20]  J. Quintana,et al.  [Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study]. , 1997, Revista medica de Chile.

[21]  J. Chesebro,et al.  Mechanisms Determining Course and Outcome of Diabetic Patients Who Have Had Acute Myocardial Infarction , 1997, Annals of Internal Medicine.

[22]  C. Lang,et al.  Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. , 1995, The American journal of cardiology.

[23]  J H Shih,et al.  Sample size calculation for complex clinical trials with survival endpoints. , 1995, Controlled clinical trials.

[24]  W. Wang,et al.  Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. , 1994, Hypertension.

[25]  S. Whitebread,et al.  Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. , 1987, The Journal of pharmacology and experimental therapeutics.

[26]  J. López-Sendón,et al.  The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction , 2004, Cardiovascular Drugs and Therapy.

[27]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .